Thermo Fisher Scientific (TMO), a leading global manufacturer of equipment for clinical and laboratory medical research, recently released a strong report for Q3FY15. According to the report, adjusted EPS rose 5% y-o-y to $1.80, outpacing analysts’ estimates by 2 cents. Revenue fell 1.2% y-o-y to $4.12 bn due to the negative impact of currency fluctuations. Organic revenue growth amounted to 4% y-o-y. The company’s management upgraded its financial forecast for 2015. Revenue will increase to $16.81-16.91 bn (previous forecast was $16.72-16.86 bn), adjusted EPS will reach $7.33-7.41 (previous forecast - $7.28-7.41). I’m upbeat about the company’s shares. Thermo Fisher is recognized as a leading developer of new techniques and special equipment in the field of medical testing and diagnosis, and new generation of sequencing equipment (recognition of sequence of proteins and nucleotides in molecules of proteins and DNA). Thus, new Ion S5 and Ion S5 XL sequencing systems, developed by the company, will be soon supplied to research and medical laboratories, which will positively affect the company’s financial performance. So, I rate Thermo Fisher Scientific (TMO) as a Buy in the mid-term. $TMO, Thermo Fisher Scientific Inc / 1440